Clinical prevention of gastric cancer by Helicobacter pylori eradication therapy: a systematic review

Helicobacter pylori (H. pylori) infection plays an important role in gastric carcinogenesis. We conducted a systematic review concerning gastric cancer development after H. pylori eradication therapy. In total 15 papers matched our criteria, the results were reviewed. The H. pylori eradication thera...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology 2009-05, Vol.44 (5), p.365-371
Main Authors: Ito, Masanori, Takata, Shunsuke, Tatsugami, Masana, Wada, Yoshihiro, Imagawa, Shinobu, Matsumoto, Yoshiaki, Takamura, Akemi, Kitamura, Shosuke, Matsuo, Taiji, Tanaka, Shinji, Haruma, Ken, Chayama, Kazuaki
Format: Article
Language:English
Subjects:
Abdominal Surgery
Colorectal Surgery
Gastroenterology
Helicobacter Infections - complications
Helicobacter Infections - drug therapy
Helicobacter pylori
Hepatology
Humans
Medicine
Medicine & Public Health
Review
Stomach Neoplasms - microbiology
Stomach Neoplasms - pathology
Stomach Neoplasms - prevention & control
Surgical Oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Helicobacter pylori (H. pylori) infection plays an important role in gastric carcinogenesis. We conducted a systematic review concerning gastric cancer development after H. pylori eradication therapy. In total 15 papers matched our criteria, the results were reviewed. The H. pylori eradication therapy statistically diminished the prevalence of clinical gastric cancer by approximately one-third. The studies from Japan supported this conclusion; however, studies from overseas reported conflicting results. The differences in these conclusions lie in the diagnostic ability of endoscopic examination, since the clinical stage was quite different between these studies. Gastric cancer that developed after eradication revealed a mainly intestinal type histology and depressed-type appearance. The following are possible reasons for reduced gastric cancer: (1) eradication therapy inhibits the new occurrence of gastric cancer, (2) eradication regresses or inhibits the growth of gastric cancer, and (3) eradication interferes with the discovery of gastric cancer. Considering the biological nature of cancer cell proliferation, a sufficiently long-term follow-up may clarify the effect of eradication therapy on inhibition of the development (not discovery) of gastric cancer and reduction of gastric cancer-related mortality.
ISSN:0944-1174
1435-5922
DOI:10.1007/s00535-009-0036-8